Ergoloid mesylates (USAN), co-dergocrine mesilate (BAN) or dihydroergotoxine mesylate, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids (dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine).
|Other names||Co-dergocrine, dihydroergotoxine|
|Elimination half-life||3.5 hours|
|CompTox Dashboard (EPA)|
|(what is this?)|
There is some evidence suggesting that potentially effective doses may be higher than those currently approved in dementia treatment.
Ergoloid Mesylate Tablets USP for sublingual use contain 1 mg of Ergoloid Mesylates USP, a mixture of the methanesulfonate salt of the following hydrogenated alkaloids: Dihydroergocornine mesylate 0.333 mg, Dihydroergocristine mesylate 0.333 mg, Dihydroergocryptine mesylate 0.333 mg.
Mechanism of actionEdit
Despite the fact that this drug has been used in the treatment of dementia for many years, its mechanism of action is still not clear. It stimulates dopaminergic and serotonergic receptors and blocks alpha-adrenoreceptors. Current studies imply that the major effect of hydergine may be the modulation of synaptic neurotransmission rather than solely increasing blood flow as was once thought. A prominent feature that accompanies aging is an increase in monoamine oxidase (MAO) levels. This results in decreased availability of catecholamines in the synaptic cleft. In one study, an interaction between age and hydergine treatment was observed in the hypothalamus, hippocampus and cerebellum. The hydergine effect was more pronounced in the aged group in the hypothalamus and cerebellum, and more pronounced in the adult in the hippocampus. These findings imply that increased brain MAO activity in aging can be modified by hydergine treatment in some brain regions.
Ergoloid is contraindicated in individuals who have previously shown hypersensitivity to the drug. They are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology. Specific drug interactions are unknown but it has been claimed that there are multiple potential interactions.
Adverse effects are minimal. The most common include transient, dose dependent nausea and gastrointestinal disturbances, and sublingual irritation with SL tablets. Other common side effects include:
- Cardiovascular: orthostatic hypotension, bradycardia
- Dermatologic: skin rash, flushing
- Ocular: blurred vision
- Respiratory: nasal congestion
- Possible risk of fibrosis and ergotism.[failed verification]
As a result of the last-mentioned effects, the use of ergoline derivatives for the treatment of blood circulation disorders, memory problems, sensation problems and the treatment of migraine is no longer permitted in some EU countries because the risks are believed to outweigh any benefits. However, this concern may be unnecessarily suppressing the use of ergoline medications.
Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin, Hydrine (Thailand)
- Flynn BL, Ranno AE (February 1999). "Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives". The Annals of Pharmacotherapy. 33 (2): 188–97. doi:10.1345/aph.17172. PMID 10084415. S2CID 12524454.
- Schneider LS, Olin JT (August 1994). "Overview of clinical trials of hydergine in dementia". Archives of Neurology. 51 (8): 787–98. doi:10.1001/archneur.1994.00540200063018. PMID 8042927.
- "Ergoloid". Drugs.com. Retrieved 2 August 2013.
- Schiff PL (October 2006). "Ergot and its alkaloids". American Journal of Pharmaceutical Education. 70 (5): 98. doi:10.5688/aj700598. PMC 1637017. PMID 17149427.
- Markstein R (1985). "Hydergine: interaction with the neurotransmitter systems in the central nervous system". Journal de Pharmacologie. 16 Suppl 3 (Suppl 3): 1–17. PMID 2869188.
- Rowell PP, Larson BT (July 1999). "Ergocryptine and other ergot alkaloids stimulate the release of [3H]dopamine from rat striatal synaptosomes". Journal of Animal Science. 77 (7): 1800–6. doi:10.2527/1999.7771800x. PMID 10438027.
- Kennedy GJ, Tanenbaum S (Dec 2000). "Suicide and aging: international perspectives". The Psychiatric Quarterly. 71 (4): 345–62. doi:10.1023/a:1004636307592. PMID 11025912. S2CID 35607526.
- "Drugs to Treat Alzheimer's Disease". Journal of Psychosocial Nursing & Mental Health Services. 52 (4): 21–22. April 2014.
- Majumdar A, Mangal NS (July 2013). "Hyperprolactinemia". Journal of Human Reproductive Sciences. 6 (3): 168–75. doi:10.4103/0974-1208.121400. PMC 3853872. PMID 24347930.
- "Ergot derivatives: restricted use" (PDF). WHO Drug Information. 27 (3): 225. 2013.
- Helsen V, Decoutere L, Spriet I, Fagard K, Boonen S, Tournoy J (2013). "Ergotamine-induced pleural and pericardial effusion successfully treated with colchicine". Acta Clinica Belgica. 68 (2): 113–5. doi:10.2143/ACB.3138. PMID 23967719. S2CID 24802394.
- Zajdel P, Bednarski M, Sapa J, Nowak G (April 2015). "Ergotamine and nicergoline - facts and myths". Pharmacological Reports. 67 (2): 360–3. doi:10.1016/j.pharep.2014.10.010. PMID 25712664.
- Steinhilber D, Schubert-Zsilavecz M, Roth HJ (2005). Medizinische Chemie (in German). Stuttgart, Germany: Deutscher Apotheker Verlag. p. 142. ISBN 3-7692-3483-9.